During normal cellular growth patterns new blood vessels are formed to provide a vascular network to enable nutrients and oxygen enter and for waste to leave the system. This process is referred to as Angiogenesis. Tumors are unregulated cellular growths but they still require oxygen and nutrients to be able to grow, depriving tumors of either oxygen or nutrients would halt tumor growth or trigger tumor reduction through apoptosis. Since tumors are unregulated growth they require a more efficient or extensive vascular system than normal tissues hence angiogenic processes represent a possible chemotherapeutic target with angiogenesis selective inhibitors. Research has demonstrated over twenty different factors that regulate angiogenic processes providing a rich source of potential targets for angiogenesis pathway inhibitors. These all angiogenesis antagonists and either directly or indirectly affect the angiogenic processes. Angiogenesis inhibition takes advantage of known factors to develop precisely-structured proteins with known biological effects. Angiogenesis inhibitor drugs. can consist of small molecules such Marimastat or modified proteins such Bevacizumab.

Angeneosis inhibitors, cancer and their potential uses:

Bevacizumab - Bevacizumab is marketed under the trade name Avastin by Genetech and Roche. It is widely used in colorectal, NSCLC, breast, kidney cancers and in glioblastomas. Bevacizumab is a monoclonal antibody that was derived from a mouse model that has been adapted for use in the human system.[9] Bevacizumab does not appear to be able to cure any form of tumor development but has significantly prolonged the life of many subjects. Typically Bevacizumab is used in combination with traditional chemotherapy with some notable success [10-14]. The disadvantage of Bevacizumab is its very high cost, $100, 000 per patient for approximately 2-3 months extended life. Most insurance companies and medical services do not fund Bevacizumab treatments due to the extremely high cost.

Marimastat – Marimastat was introduced in 1998 as an inhibitor targeting matrix metalloproteinases [15] which are proteins that degrade extracellular matrix proteins and certain biological molecules. Marimastat was a broad spectrum inhibitor but despite initial pre-clinical promise responded badly upon introduction into the clinic [16-24]. Marimastat was discontinued in 2005 but maintains a presence as a research probe into the mechanisms behind MMP inhibition.

BAY 12-9566 - BAY 12-9566 is matrix metalloproteinase (MMP) inhibitor developed by Bayer, Germany. Angiogenesis inhibitors in clinical trials demonstrated that Bay 12-9566 halted invasion by endothelial cells in a manner that was dependant on applied concentration. Clincally Bay 12-9566 demonstrated abilities to inhibit the number and volume of lung metastases but all clinical trials for this compound has been stopped and further clinical investigation is planned. [25-31]

Thalidomide – Thalidomide is a name known to the world as monster in the pharmacological industry. Poor quality research meant that Thalidomide was introduced into the market while processing disastrous teratogenicity and neuropathy. The mechanisms behind the side effects observed with Thalidomide are exactly the same as those creating interest in its anti-angiogenesis properties. Thalidomide has been reported pre-clinically as being active in prostate cancer, glioblastoma, lymphoma, arachnoiditis, Behçet's disease, and Crohn's disease. Clinically Thalidomide is approved for used in combination therapy with dexamethasone for multiple myeloma, it is under investigation at phase 1 and 2 levels in combination with tmozolamide, gemcitabine, oxalaplatin, epirubicin, cyclophosphamide and carboplatin. Many clinical trials show increased benefits of including Thalidomide in the combination and phase 3 trials involving Thalidomide are in progress indicating a new lease of life for this misused molecule.[32]

One can buy angiogenesis inhibitors from any supplier.



   1.   Goto F, Goto K et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69(5):508-517.

   2.   Stegmann TJ. FGF-1: a human growth factor in the induction of neoangiogenesis. Expert Opin Investig Drugs 1998; 7(12):2011-2015.

   3.   Schumacher B, Stegmann T et al. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg (Torino) 1998; 39(6):783-789.

   4.   Schumacher B, Pecher P et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97(7):645-650.

   5.   Haas TL, Milkiewicz M et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000; 279(4):H1540-H1547.

   6.   Haas TL. Molecular control of capillary growth in skeletal muscle. Can J Appl Physiol 2002; 27(5):491-515.

   7.   Haas TL. Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol 2005; 83(1):1-7.

   8.   Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 314(1):61-68.

   9.   Los M, Roodhart JM et al. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12(4):443-450.

10.   Lai A, Tran A et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29(2):142-148.

11.   Finn RS, Bentley G et al. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009; 29(2):284-290.

12.   Lai A, Filka E et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71(5):1372-1380.

13.   Garcia AA, Hirte H et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26(1):76-82.

14.   Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006; 5(5):363-367.

15.   Davidson S. Is British Biotech's Marimastat a major cancer drug? Nat Biotechnol 1996; 14(7):819-820.

16.   Millar AW, Brown PD et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998; 45(1):21-26.

17.   Wojtowicz-Praga S, Torri J et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16(6):2150-2156.

18.   Bramhall SR, Schulz J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87(2):161-167.

19.   Miller KD, Gradishar W et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 2002; 13(8):1220-1224.

20.   Quirt I, Bodurth A et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2002; 20(4):431-437.

21.   Coudert B. Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer. Cancer Treat Rev 2003; 29(2):127-129.

22.   Toppmeyer DL, Gounder M et al. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit 2003; 9(8):I99-104.

23.   Sparano JA, Bernardo P et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22(23):4683-4690.

24.   Wall L, Talbot DC et al. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer 2004; 90(4):800-804.

25.   Molina JR, Reid JM et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005; 16(9):997-1002.

26.   Hirte H, Goel R et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol 2000; 11(12):1579-1584.

27.   Hirte H, Vergote IB et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol 2006; 102(2):300-308.

28.   Nozaki S, Sissons S et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin Exp Metastasis 2003; 20(5):407-412.

29.   Hirte H, Stewart D et al. An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Invest New Drugs 2005; 23(5):437-443.

30.   Goel R, Chouinard E et al. An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Invest New Drugs 2005; 23(1):63-71.

31.   Gatto C, Rieppi M et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999; 5(11):3603-3607.

32.   Bouscary D, Legros L et al. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 2005; 131(5):609-618.